182 related articles for article (PubMed ID: 21540460)
1. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
4. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
6. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation.
Bornhauser M; Thiede C; Babatz J; Schetelig J; Illmer T; Kiani A; Platzbecker U; Herr W; Rieber EP; Ehninger G; Schmitz M
Leukemia; 2006 Nov; 20(11):2055-7. PubMed ID: 16990776
[No Abstract] [Full Text] [Related]
7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
8. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
9. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
10. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
11. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
12. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
13. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.
Zuckerman T; Katz T; Haddad N; Fineman R; Dann EJ; Avivi I; Ofran Y; Gavish I; Faibish T; Sahar D; Hertz E; Sabo E; Reisner Y; Rowe JM
Am J Hematol; 2012 Sep; 87(9):875-9. PubMed ID: 22847303
[TBL] [Abstract][Full Text] [Related]
15. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.
Rezvani K; Price DA; Brenchley JM; Kilical Y; Gostick E; Sconocchia G; Hansmann K; Kurlander R; Douek DC; Barrett AJ
Cytotherapy; 2007; 9(3):245-51. PubMed ID: 17464756
[TBL] [Abstract][Full Text] [Related]
16. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.
Chalandon Y; Passweg JR; Guglielmi C; Iacobelli S; Apperley J; Schaap NP; Finke J; Robin M; Fedele R; Bron D; Yakoub-Agha I; van Biezen A; de Witte T; Kröger N; Olavarria E;
Haematologica; 2014 Sep; 99(9):1492-8. PubMed ID: 24997146
[TBL] [Abstract][Full Text] [Related]
17. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
[TBL] [Abstract][Full Text] [Related]
18. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.
Borchers S; Provasi E; Silvani A; Radrizzani M; Benati C; Dammann E; Krons A; Kontsendorn J; Schmidtke J; Kuehnau W; von Neuhoff N; Stadler M; Ciceri F; Bonini C; Ganser A; Hertenstein B; Weissinger EM
Hum Gene Ther; 2011 Jul; 22(7):829-41. PubMed ID: 21091264
[TBL] [Abstract][Full Text] [Related]
19. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
Shimoni A; Gajewski JA; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2001; 7(10):568-75. PubMed ID: 11760089
[TBL] [Abstract][Full Text] [Related]
20. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
